Literature DB >> 22340587

PI3King on MYCN to improve neuroblastoma therapeutics.

Michael D Hogarty1, John M Maris.   

Abstract

MYCN is an oncogenic driver of childhood neuroblastoma, a frequently lethal pediatric tumor. In a recent paper in Science Translational Medicine, Chanthery and colleagues demonstrate that PI3K inhibition leads to the dual therapeutic benefits of enhanced MYCN degradation and loss of a paracrine angiogenic signal mediated by MYCN. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Year:  2012        PMID： 22340587     DOI： 10.1016/j.ccr.2012.01.018

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  10 in total

1.  ALK and MYCN: when two oncogenes are better than one.

Authors:  Zhihui Liu; Carol J Thiele
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

2.  Calreticulin regulates MYCN expression to control neuronal differentiation and stemness of neuroblastoma.

Authors:  Andy Chi-Lung Lee; Yu-Yin Shih; Fanfan Zhou; Tsi-Chian Chao; Hsinyu Lee; Yung-Feng Liao; Wen-Ming Hsu; Ji-Hong Hong
Journal:  J Mol Med (Berl)       Date:  2019-01-05       Impact factor: 4.599

3.  The P2X7 receptor is a key modulator of the PI3K/GSK3β/VEGF signaling network: evidence in experimental neuroblastoma.

Authors:  F Amoroso; M Capece; A Rotondo; D Cangelosi; M Ferracin; A Franceschini; L Raffaghello; V Pistoia; L Varesio; E Adinolfi
Journal:  Oncogene       Date:  2015-01-26       Impact factor: 9.867

4.  Reorganization of metastamiRs in the evolution of metastatic aggressive neuroblastoma cells.

Authors:  Faizan H Khan; Vijayabaskar Pandian; Satishkumar Ramraj; Sheeja Aravindan; Terence S Herman; Natarajan Aravindan
Journal:  BMC Genomics       Date:  2015-07-07       Impact factor: 3.969

5.  Target delivery of MYCN siRNA by folate-nanoliposomes delivery system in a metastatic neuroblastoma model.

Authors:  Qiqi Zhu; Chen Feng; Weiwei Liao; Yan Zhang; Suoqin Tang
Journal:  Cancer Cell Int       Date:  2013-06-27       Impact factor: 5.722

6.  MYCN‑amplified neuroblastoma cell‑derived exosomal miR‑17‑5p promotes proliferation and migration of non‑MYCN amplified cells.

Authors:  Weiming Chen; Xiwei Hao; Binyi Yang; Yuezhen Zhang; Lingyun Sun; Yanan Hua; Li Yang; Jiabin Yu; Jing Zhao; Lin Hou; Hongting Lu
Journal:  Mol Med Rep       Date:  2021-02-04       Impact factor: 2.952

7.  A novel cuproptosis-related subtypes and gene signature associates with immunophenotype and predicts prognosis accurately in neuroblastoma.

Authors:  Xiao-Mao Tian; Bin Xiang; Yi-Hang Yu; Qi Li; Zhao-Xia Zhang; Chenghao Zhanghuang; Li-Ming Jin; Jin-Kui Wang; Tao Mi; Mei-Lin Chen; Feng Liu; Guang-Hui Wei
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

Review 8.  Molecular targeting therapies for neuroblastoma: Progress and challenges.

Authors:  Atif Zafar; Wei Wang; Gang Liu; Xinjie Wang; Wa Xian; Frank McKeon; Jennifer Foster; Jia Zhou; Ruiwen Zhang
Journal:  Med Res Rev       Date:  2020-11-06       Impact factor: 12.944

9.  Molecular mechanisms of MYCN-dependent apoptosis and the MDM2-p53 pathway: an Achille's heel to be exploited for the therapy of MYCN-amplified neuroblastoma.

Authors:  Marialaura Petroni; Veronica Veschi; Alberto Gulino; Giuseppe Giannini
Journal:  Front Oncol       Date:  2012-10-12       Impact factor: 6.244

10.  Focal DNA copy number changes in neuroblastoma target MYCN regulated genes.

Authors:  Candy Kumps; Annelies Fieuw; Pieter Mestdagh; Björn Menten; Steve Lefever; Filip Pattyn; Sara De Brouwer; Tom Sante; Johannes Hubertus Schulte; Alexander Schramm; Nadine Van Roy; Tom Van Maerken; Rosa Noguera; Valérie Combaret; Christine Devalck; Frank Westermann; Geneviève Laureys; Angelika Eggert; Jo Vandesompele; Katleen De Preter; Frank Speleman
Journal:  PLoS One       Date:  2013-01-04       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.